amikacin has been researched along with cysteamine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| De Maio, F; De Spirito, M; Delogu, G; Fimia, GM; Goletti, D; Maulucci, G; Palucci, I; Petrone, L; Piacentini, M; Romagnoli, A; Sali, M; Sanguinetti, M | 1 |
| D'Eletto, M; De Maio, F; Delogu, G; Goletti, D; Occhigrossi, L; Paglione, F; Palucci, I; Pereyra Boza, MDC; Piacentini, M; Rossin, F; Sali, M; Salustri, A; Sanguinetti, M | 1 |
1 review(s) available for amikacin and cysteamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for amikacin and cysteamine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Autophagy; Cystamine; Cysteamine; DNA Replication; Drug Synergism; Granuloma; GTP-Binding Proteins; Humans; Macrophages; Mycobacterium tuberculosis; Protein Glutamine gamma Glutamyltransferase 2; THP-1 Cells; Transglutaminases; Tuberculosis, Multidrug-Resistant | 2019 |
Cysteamine/Cystamine Exert Anti-
Topics: Amikacin; Anti-Bacterial Agents; Cystamine; Cysteamine; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2023 |